Surface Oncology, Inc. (SURF) Social Stream



Surface Oncology, Inc. (SURF): $0.78

0.00 (-0.23%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add SURF to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals

Industry

D

Ranked

#83 of 168

in industry

SURFACE ONCOLOGY INC (SURF) Price Targets From Analysts

Use the tables below to see what analysts covering SURFACE ONCOLOGY INC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-08 5 $17 $14 $15 $0.87 1624.14%
2022-03-03 5 $17 $10 $13.75 $0.87 1480.46%
2022-05-10 4 $17 $10 $13.666 $0.87 1470.8%
2022-05-11 4 $17 $10 $13 $0.87 1394.25%
2022-08-04 3 $12 $10 $11 $0.87 1164.37%
2022-08-08 3 $12 $8.5 $10.25 $0.87 1078.16%
2023-03-10 2 $6 $3 $5.25 $0.87 503.45%
2023-05-05 3 $6 $3 $5.25 $0.87 503.45%

The Trend in the Analyst Price Target


Over the past 36 months, SURF's average price target has gone down $5.08.

SURF reports an average of 538.01% for its upside potential over the past 39 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-08-08 3 12 8.5 10.25 1.800 469.44%
2022-11-03 3 6 3.0 5.25 1.230 326.83%
2022-11-03 2 6 3.0 5.25 1.230 326.83%
2023-03-10 2 6 3.0 5.25 0.677 675.48%
2023-05-05 3 6 3.0 5.25 0.596 780.87%

SURF Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 3 0 0 0 0 3

The Trend in the Broker Recommendations


Over the past 36 months, SURF's average broker recommendation rating improved by 0.33.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for SURF as an investment opportunity.

  • In the context of all US stocks, SURFACE ONCOLOGY INC's upside potential (average analyst target price relative to current price) is higher than 1067.36% of them.
  • To contextualize these metrics, consider that out of all US stocks, SURFACE ONCOLOGY INC's average analyst price target is greater than 145.74% of them.
  • SURF has a higher number of analysts covering the stock than 196.18% of Healthcare stocks.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, SURFACE ONCOLOGY INC's variance in analysts' estimates is lower than -184.48% of them.

In the Pharmaceutical Products industry, ERYP, SLDB, and XFOR are the three stocks most similar to SURFACE ONCOLOGY INC regarding the price target and analyst recommendation information presented here.

Is SURF a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8135 seconds.